<?xml version="1.0" encoding="UTF-8"?>
<p>The management of drug-induced long QT syndrome focuses on the identification of patients at risk of developing long QT, the monitoring QT duration during treatment, the early recognition of QT prolongation, and the correction of reversible causes and treatment of life-threatening arrhythmia, namely TdP. Before starting a new treatment with a potential risk of QT prolongation, the patient's medical profile should be reviewed carefully to avoid concomitant use of other QT prolonging therapy. There are more than 50 FDA approved medications with a risk of QT prolongation (a comprehensive list can be found on 
 <ext-link ext-link-type="uri" xlink:href="https://www.crediblemeds.org" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.crediblemeds.org</ext-link>). Special attention is needed to those commonly used non-cardiac medications that can potentially prolong QT duration such as antiemetic drugs.
 <sup>
  <xref rid="bibr45" ref-type="bibr">45</xref>
 </sup> It is not uncommon to have electrolyte imbalances during an acute illness such as COVID-19 infection so careful electrolyte monitoring is recommended.
</p>
